Saturday, 27 April 2019

The Secret of Why Are Biomarkers Needed For Prostate Cancer

Prostate cancer is the greatest common cancer among men (after skin cancer), but it can frequently be treated positively. Prostate cancer originates when cells in the prostate gland start to grow uncontrollably. The prostate is a gland establish only in males. It makes some of the fluid that is a portion of semen. 





Types of prostate cancer

Virtually all prostate cancers are adenocarcinomas. These cancers advance from the gland cells (the cells that create the prostate the fluid that is added to the semen).
Further types of prostate cancer include:
                     Sarcomas
                     Small cell carcinomas
                     Neuroendocrine tumors
                     Transitional cell carcinomas

These other types of prostate cancer are rare. If you have prostate cancer it is nearly definite to be an adenocarcinoma.




The prostate-specific antigen (PSA) biomarker has been broadly used to screen men for prostate cancer. Examines of PSA cancer-specific sensation and specificity occur; opportunely, a novel generation of PCa biomarkers is developing, consisting of serum-, urine-, and tissue-based assays that may supplement PSA testing, or exchange it over time



There are several reasons why biomarkers are needed for prostate cancer, including
(i) For consistent diagnosis of important prostate cancer and making therapy decisions
(ii) For an early estimate of prognosis of the upcoming course of the disease, which may lead to adjusted monitoring and improved therapy
(iii) For calculation of therapy response and thus stratifying potential treatment benefit
(iv) The identification of another therapeutic target created on molecular analyses (eg. target expression and mutational status);
(v) Emerging individualized dealing options and thus recover patient outcomes
(vi) Standardization of study/cohort design, authorizing identical reporting. The ideal biomarker would be non-invasive/minimally invasive, have high accuracy and performance, and at low cost.
Most important is choosing the accurate biomarker at the correct time, whether a diagnostic or prognostic biomarker. Some of the more commonly used biomarkers, 4Kscore, PCA3, SelectMDx, ConfirmMDx, OncotypeDx, Prolaris and Decipher.


Check our Conference Session Biomarkers
J U L Y 15-16, 2019 | Abu Dhabi, U A E
                   Click to know more: https://biomarkerscongress.conferenceseries.com/

No comments:

Post a Comment